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Abstract
Background: Tumor microenvironments present significant barriers to penetration by antibodies and immunoconjugates.
Tumor microenvironments, however, are difficult to study in vitro. Cells cultured as monolayers exhibit less resistance to
therapy than those grown in vivo and an alternative research model more representative of the in vivo tumor is more
desirable. SS1P is an immunotoxin composed of the Fv portion of a mesothelin-specific antibody fused to a bacterial toxin
that is presently undergoing clinical trials in mesothelioma.
Methodology/Principal Findings: Here, we examined how the tumor microenvironment affects the penetration and killing
activity of SS1P in a new three-dimensional (3D) spheroid model cultured in vitro using the human mesothelioma cell line
(NCI-H226) and two primary cell lines isolated from the ascites of malignant mesothelioma patients. Mesothelioma cells
grown as monolayers or as spheroids expressed comparable levels of mesothelin; however, spheroids were at least 100
times less affected by SS1P. To understand this disparity in cytotoxicity, we made fluorescence-labeled SS1P molecules and
used confocal microscopy to examine the time course of SS1P penetration within spheroids. The penetration was limited
after 4 hours. Interestingly, we found a significant increase in the number of tight junctions in the core area of spheroids by
electron microscopy. Expression of E-Cadherin, a protein involved in the assembly and sealing of tight junctions and highly
expressed in malignant mesothelioma, was found significantly increased in spheroids as compared to monolayers.
Moreover, we found that siRNA silencing and antibody inhibition targeting E-Cadherin could enhance SS1P immunotoxin
therapy in vitro.
Conclusion/Significance: This work is one of the first to investigate immunotoxins in 3D tumor spheroids in vitro. This initial
description of an in vitro tumor model may offer a simple and more representative model of in vivo tumors and will allow for
further investigations of the microenvironmental effects on drug penetration and tumor cell killing. We believe that the
methods developed here may apply to the studies of other tumor-targeting antibodies and immunoconjugates in vitro.
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Introduction
Solid tumors remain a major problem despite a vast number of
anti-cancer agents available. Advances in antibody-based therapies
represent a promising new approach to treating solid cancer, yet a
major challenge involves delivering sufficient amounts of antibod-
ies and immunoconjugates within tumor masses [1]. For an anti-
cancer antibody agent to be successful, it must satisfy two
requirements: (a) the agent must be effective in the tumor
microenvironment, and (b) the agent must reach the tumor cells
in optimal quantities.
Tumor microenvironments are difficult to study in vivo and have
been extensively studied primarily at the monolayer level in vitro.
Cancer cells cultured as monolayers exhibit less resistance to
therapy than those grown in vivo and may be explained by
‘‘multicellular resistance,’’ a mechanism for drug resistance
attributed to cell-cell contacts, cell-matrix contacts, and the
three-dimensional (3D) shape found in tissue [2–4]. Multicellular
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resistance acquired by tumor cells may contribute to difficulties in
translating promising findings from in vitro studies into therapy [5].
In vitro multicellular cancer spheroids, therefore, have begun to
bridge the complexity gap between monolayer cell culture and in
vivo tumors and have become valuable models in the study of drug
resistance [6].
Mesothelioma is a fatal cancer of the mesothelium and
predominantly forms from previous exposure to asbestos [7].
Malignant mesothelioma (MM) is often resistant to chemotherapy
[8] and radiation [9]. Prognosis is poor and average survival
ranges from a few months to less than 2 years [10]. To investigate
apoptotic resistance in mesothelioma, Broaddus and colleagues
recently reported that mesothelioma cells acquired resistance
when formed into 3D spheroids in vitro [11]. These spheroids
exhibited many features of the tumor microenvironment,
modeling the avascular region of tumors that is dependent on
diffusion. Antibody-based therapy has emerged as a new
promising strategy to treat mesothelioma and other solid tumors
[12]. However, tumor microenvironments that present significant
barriers to penetration by antibodies and immunoconjugates have
been studied only in vivo. A simple, reliable, high-throughput and
less expensive in vitro tumor model should be very useful for
characterizing and screening antibodies and immunoconjugates
for cancer therapy.
Mesothelin is a tumor differentiation antigen that is normally
expressed in low levels on the mesothelial cells lining the pleura,
peritoneum and pericardium [12]. Mesothelin is highly expressed
in mesothelioma, as well as ovarian cancer and lung cancer
[12,13], and has been shown to be a biomarker for the diagnosis of
mesothelioma [14]. Although the biological function of mesothelin
remains unclear, mesothelin’s limited expression in normal tissue
and high expression in various cancers make it an attractive
candidate for immunotherapy [12]. The mucin CA125/MUC16
is also highly expressed at the cell surface in mesothelioma and
ovarian cancer [15]. The binding of mesothelin to CA125/
MUC16 may play a role in the implantation and peritoneal spread
of tumors by cell adhesion [15]. The recombinant immunotoxin
SS1P is currently in clinical trials for mesothelioma. SS1P is
composed of the Fv portion of an anti-mesothelin monoclonal
antibody (mAb) fused to a 38 kDa Pseudomonas exotoxin-A (PE)
fragment [12]. After binding to mesothelin, the immunotoxin is
internalized, undergoes processing in the endocytic compartment
and the immunotoxin fragment containing the ADP-ribosylation
domain is transported to the endoplasmic reticulum. It is then
translocated to the cytosol where it inhibits elongation factor-2
leading to inhibition of protein synthesis and ultimately cell death.
The goal of the present work is to establish a basic in vitro 3D
spheroid model of human mesothelioma and to investigate how
the tumor microenvironment affects the penetration and killing
activity of the immunotoxin SS1P targeting mesothelioma. This
approach shows that 3D tumor microenvironments increase the
number of tight junctions and inhibit SS1P penetration within
tumor spheroids. We also demonstrate how this new method can
be used to identify potential new therapeutic targets (e.g., E-
Cadherin) highly expressed in 3D mesothelioma, but not in
monolayers. The method developed here is simple and may easily
apply to the studies of other tumor-targeting antibodies and
immunoconjugates in vitro.
Methods
Cell lines
The human mesothelioma cell line NCI-H226 was obtained
from the American Type Culture Collection (ATCC; Rockville,
MD). The cell line was maintained as adherent monolayer cultures
in RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented
with 10% fetal bovine serum (HyClone, Logan, UT), L-glutamine,
pyruvate, nonessential amino acids, and penicillin-streptomycin
(Invitrogen) and incubated in 5% CO2 with balance of air at 37uC.
Cells were seeded at 26105/mL in T-75 tissue culture flasks
(Corning Incorporated, Acton, MA). After four days of growth,
this cell density did not produce confluence. Cells were harvested
and the media were changed twice a week. Cells were confirmed
to be negative for mycoplasma.
The two primary cell lines (NCI-M-03 and NCI-M-13) were
established from the ascites of MM patients being treated at the
National Cancer Institute (NCI). The ascites were obtained on
Institutional Review Board approved protocols and patients signed
informed consent. Briefly, the ascites (100–1000 mL) were
collected and spun down at 1000 rpm at room temperature for
5 minutes; the cell pellets were washed twice with PBS, red blood
cells were removed by BD Pharm LyseTM-Lysing Buffer kit (BD
Bioscience, Franklin Lakes, NJ) according to the manufacturer’s
instructions. The cells were resuspended in RPMI 1640 (Invitro-
gen) supplemented with 20% fetal bovine serum (Lonza,
Walkersville, MD), 2 mM Glutamine (Invitrogen), 100 units
penicillin-streptomycin (Invitrogen), and 1 mM Sodium Pyruvate
(Invitrogen). The cells were seeded into 175 mL culture flasks at a
density of 2.5–4.06105 cells/mL. After a 24 hour incubation at
37uC in a humidified, 5% CO2 atmosphere overnight, the
medium containing non-adherent cells was replaced with fresh
medium. The media were changed twice a week.
Spheroid formation
A 96-well Greiner suspension culture plate (Sigma, St. Louis,
MO) was coated with 50 mL of 5 mg/mL of poly-HEMA (poly-2-
hydroxyethyl methacrylate; Sigma-Aldrich) in 95% ethanol and
evaporated with lid on at room temperature for 72 hours [11].
Mesothelioma cells were grown to near confluency and dissociated
into single cells with Accutase (BD Biosciences, San Jose, CA).
Each well contained 10,000 cells for one spheroid. The plate was
then centrifuged at 1000 rpm for 10 minutes to initiate cell-cell
interaction and incubated at 37uC, 5% CO2 for 24 hours. The
spheroids are stable for 48–72 hours and can be easily transferred
using a regular pipette without dissociating.
To treat spheroids with an inhibitory mAb against E-Cadherin,
a pretreatment group of NCI-H226 cells was incubated with 1 mg/
mL of SHE78-7 (cat. #13-5700; Invitrogen) for 30 minutes and
then seeded as spheroids. The post-treatment group of cells was
seeded as spheroids and then incubated with 1 mg/mL of SHE78-
7 for 30 minutes. Both groups of spheroids were incubated for
48 hours and then treated with different concentrations of SS1P or
BL22 as a PE toxin control or cycloheximide (Sigma) as a positive
control. Finally, cell growth inhibition or viability assays were
performed to assess the anti-tumor activity of SS1P.
Flow cytometry
Cells were incubated with 5 mg/mL of MN (mesothelin mAb;
cat. # 200-301-A88; Rockland, Gilbertsville, PA). Binding was
detected with goat anti-mouse IgG conjugated with Alexa488
(Sigma-Aldrich). The fluorescence associated with the live cells was
measured using FACSCalibur (BD Biosciences).
Cell growth and viability assays
Cell growth was measured by WST assays. Ten thousand NCI-
H226 cells were seeded in each well of a 96-well plate as either
monolayer or spheroids, and each well was treated with different
concentrations of SS1P or BL22 at 24 hours. Cycloheximide at
3D Mesothelioma Spheroids
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10 mg/mL was used as a positive control. The samples were
incubated at 37uC, 5% CO2 for 72 hours, when monolayer
samples had reached approximately 80% confluency. Cell viability
was measured using the WST-8 Cell Proliferation Assay Kit
(Dojindo, Rockville, MD) [13]. Briefly, monolayer cells were
incubated with WST-8 for 2–3 hours while spheroids were
incubated overnight at 37uC. The absorbance of the sample at
450 nm was measured with a reference wavelength of 650 nm.
Cell growth inhibition was expressed as 50% inhibition of cell
viability, which is halfway between the level of viability in the
absence of toxin and that in the presence of cycloheximide.
Cell viability was assessed by an ATP measurement assay. Ten
thousand NCI-H226 cells were seeded in each well of a 96-well
plate as either monolayer or spheroids in RPMI growth media,
and each well was treated with different concentrations of SS1P or
BL22 at 24 hours. The samples were incubated at 37uC, 5% CO2
for 72 hours. Cell viability was measured using the CellTiter-Glo
Luminescent Cell Viability Assay Kit (Promega, Madison, WI).
Briefly, cells were incubated with CellTiter-Glo Reagent and
mixed on an orbital shaker for 2 minutes to induce cell lysis and
incubated at room temperature for 10 minutes to stabilize
luminescent signal. The absorbance of the sample was measured
in terms of relative light units using VICTOR3 Multilabel
Counter model 1420 (PerkinElmer Life Sciences, Waltham, MA).
To evaluate the anti-tumor cytotoxicity of SS1P on primary
mesothelioma cell lines, 56104/well of cells were seeded in a 24-
well plate. The following immunotoxins were added at various
concentrations: SS1P (0, 0.1, 1, 10 and 100 ng/mL), BL22, an
immunotoxin against human CD22, as a negative control (0, 0.1,
1, 10 and 100 ng/mL) and HB21, an immunotoxin recognizing
the human transferrin receptor, as a positive control at 10 ng/mL.
Cells were incubated for 96 hours, then washed twice with PBS;
fixed with 10% neutral buffered formalin solution (Sigma) at room
temperature for 5 minutes, and crystal violet dye at a concentra-
tion of 1mg/mL was added and incubated for 5 minutes at room
temperature. The cells were washed, dried and destained in 1%
acetic acid. Color intensity was determined by a Versamax
microplate reader (Molecular Device, Sunnyvale, California) at a
wavelength of 595 nm.
Confocal laser scanning fluorescence microscopy
Confocal laser scanning fluorescence microscopy imaging (Zeiss
LSM 710; Carl Zeiss, Oberkochen, Germany) was performed by
placing spheroids in an 8-chambered borosilicate coverglass
(Thermo Fisher Scientific, Waltham, MA). SS1P was labeled with
Alexa Fluor 488 Protein Labeling Kit (Invitrogen) and incubated
with spheroids at 10 mg/mL, and 15 mm thick optical sections
were imaged every 15 minutes for 16 hours. Images were taken in
both phase contrast and green fluorescence. Fluorescence intensity
was measured with ImageJ (NIH, Bethesda, MD).
SiRNA knockdown
NCI-H226 cells were seeded in a 6-well plate at 1.56105 cells/
well in 2 mL of RPMI growth media and incubated for 24 hours.
Cells were then transfected with 400 pmol of E-Cadherin siRNA
(cat. #4390828; Ambion, Austin, TX) or Silencer siRNA as a
negative control (cat. #4390843; Ambion) in serum-free RPMI
media with 1% glutamine mixed with Oligofectamine reagent (cat.
#12252-011; Invitrogen). After 36 hours of incubation at 37uC,
5% CO2, cells were grown as monolayers or spheroids for
24 hours and then treated with different concentrations of SS1P or
BL22. The percentage of E-Cadherin knockdown was evaluated
via western blot using 150 mg of cell protein lysate per lane. Cell
growth inhibition was measured using a WST-8 assay kit.
Electron microscopy preparation
A spheroid cell pellet was fixed in 4% formaldehyde/2%
glutaraldehyde (Tousimis, Rockville, MD) in 0.1M cacodylate
buffer (pH 7.4), then post-fixed in 1% osmium tetroxide
(Electron Microscopy Sciences, Ft. Washington, PA) in the
same buffer. The pellet was dehydrated in a series of alcohol
and propylene oxide and then embedded in epoxy resin for thin-
section transmission electron microscopy (TEM) using a Hitachi
Figure 1. Establishment of human mesothelioma spheroids. A.
Monolayers and spheroids of human mesothelioma cell line, NCI-H226,
and primary mesothelioma lines NCI-M-03 and NCI-M-13. Scale bars,
400 mm (except 200 mm for NCI-M-13 spheroids). B. Immunohisto-
chemical staining of an NCI-H226 spheroid (see Methods). (a)
Mesothelin stains both the membrane and cytoplasm. (b) Calretinin
stains both the nuclei and cytoplasm. (c) HBME-1 exhibits a focal
membranous staining pattern (arrows). (d) Cytokeratin 5/6 exhibits a
focal cytoplasmic staining pattern. (e) WT-1 stains the nuclei. (f)
Thrombomodulin exhibits a focal membranous staining pattern close to
the rim (arrows).
doi:10.1371/journal.pone.0014640.g001
3D Mesothelioma Spheroids
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H7600 TEM (Hitachi, Tokyo, Japan) equipped with a charged
couple device camera (AMT, Danvers, MA). To quantitatively
evaluate cellular junctions, we examined three representative
spheroids. In each spheroid, 50 cells were randomly chosen to
calculate the numbers of tight junctions, gap junctions, and
desmosomes.
For scanning electron microscopy (SEM) using S3000N
(Hitachi) analysis, spheroids were treated in tetramethylsilane
solution (Electron Microscopy Sciences) at the end of alcohol
dehydration and then allowed to evaporate. Spheroids were lightly
coated with platinum palladium for SEM examination.
Immunohistochemistry
Immunohistochemical stains were performed and interpreted at
PhenoPath Laboratories (Seattle, WA) with optimized protocols
using a panel of standard markers for the diagnosis of MM:
mesothelin, cytokeratin 5/6, calretinin, HBME-1, thrombomodu-
lin, and WT-1.
Western blot analysis
NCI-H226 cells were allowed to grow for 48–72 hours. After
seeding until approximately 60% confluent, 26106 monolayer
cells were centrifuged and collected, washed with 1 mL PBS and
resuspended in 100 ml immunoprecipitation assay buffer contain-
ing 2% SDS and protease inhibitors (‘‘Complete Mini-EDTA
Free’’ protease inhibitor tablet, Roche, Mannheim, Germany) to
solubilize cells or spheroids [13]. Four cycles of freezing at 280u
and thawing at 37uC were repeated. Protein lysate was centrifuged
at 10,000 rpm for 1 minute, supernatant was collected and protein
concentration was measured via Coomassie Plus Protein Assay
(Thermo Scientific/Pierce, Rockford, IL). Samples containing
50 mg of cell protein lysate per lane were separated by SDS-
PAGE, transferred onto PVDF membranes, and incubated with a
primary rabbit antibody. The primary antibodies used include
E-Cadherin mAb (cat. #3195; Cell Signaling, Danvers, MA),
polyclonal anti-ZO-1 (cat. #61-7300; Invitrogen), polyclonal anti-
Connexin 32 (cat. #71-0600; Invitrogen), polyclonal anti-Mcl-1
(cat. #4572; Cell Signaling), Bcl-xL mAb (cat. #2764; Cell
Signaling), polyclonal anti-BAX (cat. #06-499; Millipore, Teme-
cula, CA), polyclonal anti-BID (cat. #2002; Cell Signaling), or
Bcl-2 mAb (cat. #2870; Cell Signaling). Primary antibodies were
detected by secondary goat anti-rabbit antibodies conjugated with
horseradish peroxidase (HRP; Invitrogen). HRP-conjugated
b-actin mAb (cat. #5125; Cell Signaling) was used as a control.
Signals were visualized by an enhanced Luminol-based chemilu-
minescent western blotting detection kit (GE Healthcare, Piscat-
away, NJ). Western blots shown are representative images of five
individual experiments.
Statistical analysis
Statistical analysis was performed with Prism (version 5) for
Windows (GraphPad Software). Raw data were analyzed by
‘‘analysis of variance’’ with Dunnett’s and Newman-Keuls
multiple comparison post tests. p values,0.05 were considered
statistically significant.
Results
Establishment of human mesothelioma spheroids
To investigate the penetration and killing activity of SS1P in
mesothelioma microenvironments in vitro, we developed 3D tumor
spheroids. Spheroids have been observed in the pleural fluid of
human MM and linked to increased malignancy [16]. We used the
NCI-H226 mesothelioma cell line, which was originally isolated
Figure 2. Anti-tumor immunotoxin activity on mesothelioma
monolayers and spheroids. Cells treated with SS1P and BL22. A. Cell
growth inhibition (WST-8 assays) of NCI-H226. IC50 of SS1P for spheroids
was.1000 ng/mL. IC50 for monolayers was,10 ng/mL. B. Cell viability
3D Mesothelioma Spheroids
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from the pleural fluid of a mesothelioma patient (ATCC), and may
also be used to grow clinically relevant MM tumors in mice (MH
and MF, unpublished data). We cultured each spheroid from
10,000 cells. After 24 hours of incubation, we found the formation
of tight spheroid disks with smooth edges which appeared to be
uniform with a diameter of approximately 700 mm with a
thickness of 150 mm (Fig. 1A). We also cultured two primary cell
lines (NCI-M-03 and NCI-M-13) from MM patients and used the
same protocol to make spheroids. As shown in Fig. 1A, NCI-M-13
formed compact mesothelioma spheroids similar to the NCI-H226
spheroids while NCI-M-03 formed mostly aggregates.
To further characterize the NCI-H226 spheroid model, we
decided to perform immunohistochemistry analysis with the
markers generally used for the diagnosis of MM. Given that there
is no overall consensus about how many and which markers
should be used, we chose a panel of recommended antibodies for
mesothelin, cytokeratin 5/6, calretinin, HBME-1, thrombomodu-
lin, and WT-1 [17]. As shown in Fig. 1B, mesothelin, calretinin
and WT-1 were expressed in almost all cancer cells. Interestingly,
HBME-1, cytokeratin 5/6 and thrombomodulin were differen-
tially expressed in the spheroid in only a few cancer cells, but not
in others. The expression of these markers in spheroids was in
general consistent with those of previously published mesothelio-
ma specimens [17,18].
Anti-tumor activity on tumor spheroids
We then used SS1P to investigate how tumor microenvironments
affect the killing activity and penetration of an antibody agent. The
NCI-H226 cells cultured as monolayers and spheroids were treated
with SS1P and the anti-CD22 immunotoxin (BL22) was included as
a negative control. In cell growth inhibition (WST) assays (Fig. 2A),
after 72 hours of immunotoxin treatment, the IC50 of SS1P for
spheroids was .1000 ng/mL, at least 100 times the IC50 for
monolayers, ,10 ng/mL. We confirmed this observation using a
cell viability (ATP) assay. As shown in Fig. 2B, the IC50 of SS1P for
spheroids was.1000 ng/mL and the IC50 for monolayers was less
than 10 ng/mL. More importantly, in both assays, greater than
50% of the cancer cells from spheroids could not be killed by SS1P
concentrations as high as 1,000 ng/mL. Finally, we tested SS1P on
primary lines isolated fromMMpatients. Both lines (NCI-M-03 and
NCI-M-13) contain mesothelin-positive tumor cells and mesothelin-
negative cells isolated from the same tumor microenvironment. In
both cell lines, 100 ng/mL of SS1P killed mesothelioma cells
expressing mesothelin, in 20–50% of monolayers (Fig. 2C).
However, SS1P was far less effective on spheroids cultured from
primary MM cell lines.
Mesothelin expression in tumor spheroids
Our first step in investigating the possible causes for increased
drug resistance was to determine whether or not it was associated
with the reduction of antigen expression. This was done by
measuring the cell surface expression of mesothelin in NCI-H226
tumor spheroids by flow cytometry. As shown in Figure 3, the
mean fluorescence intensity was 1367 for monolayer cells and
1034 for spheroid cells. This showed that the expression of
mesothelin between monolayer and spheroid cells is comparable
and indicated that the drug resistance of spheroids to SS1P was
not due to a reduction of mesothelin expression.
Since SS1P was not able to kill greater than 50% of the NCI-
H226 cells cultured as a spheroid at saturated concentrations, yet
was able to kill all of the cells cultured as a monolayer (Fig. 2), we
hypothesized that such drug resistance may be partially due to the
poor penetration of SS1P within tumors.
Penetration of immunotoxin in tumor spheroids
We made a fluorescence-labeled SS1P molecule and developed
a strategy to examine the time-lapse penetration of immunotoxin
Figure 3. Mesothelin expression in mesothelioma monolayers and spheroids. NCI-H226 cells incubated with an anti-mesothelin mAb (MN)
and detected with goat anti-mouse IgG conjugated with Alexa488 by flow cytometry.
doi:10.1371/journal.pone.0014640.g003
(CellTiter-Glo Luminescent assays) of NCI-H226. IC50 of SS1P for
spheroids was .1000 ng/mL. IC50 for monolayers was ,5 ng/mL. C.
Primary mesothelioma lines NCI-M-03 and NCI-M-13 treated with
100 ng/mL of SS1P. 2D, monolayers; 3D, spheroids. *p,0.01.
doi:10.1371/journal.pone.0014640.g002
3D Mesothelioma Spheroids
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in spheroids by confocal microscopy (supplemental videos S1 and
S2). We labeled SS1P with Alexa488 (green fluorescence) and
evaluated the cross section close to the middle of an NCI-H226
spheroid at hours 0, 8 and 16 using confocal microscopy (Fig. 4A
and 4B). At hour 0, the green fluorescence was confined to the
outer surface of the spheroid, and spread towards the center of the
spheroid at hour 8 without ever reaching the center. We then
quantitatively measured the fluorescence intensity and showed the
increase in green fluorescence (SS1P) until 4 hours, after which the
intensity plateaued (Fig. 4C). The results demonstrate the
incomplete penetration of SS1P.
Given that the mesothelin expression between spheroids and
monolayers was similar, even at a saturated concentration of
SS1P, an incomplete penetration is unlikely to be caused by the
depletion of SS1P. We therefore postulated that the incomplete
penetration of the drug may be attributed to a multicellular
resistance involving cell contact in spheroids.
Cell contact in spheroids
To investigate cellular contact in spheroids, we studied the
ultrastructure of spheroids by SEM (Fig. 5A and 5B) and TEM
(Fig. 5C and 5D). Interestingly, SEM images (Fig. 5B) show the
presence of long and branching microvilli on cell surfaces, a
feature characteristic of well-differentiated MM in vivo [19].
As shown in Figure 5 (C, D and E), TEM results show that the
overall number of tight junctions in spheroids is the highest among
Figure 4. Penetration of Alexa488-labeled immunotoxin SS1P in tumor spheroids. A. SS1P labeled with Alexa488 (green fluorescence). A
cross section close to the middle of an NCI-H226 spheroid evaluated at hours 0, 8 and 16 using confocal microscopy. B. Overlay of bright field and
fluorescence images of a spheroid. C. Mean fluorescence intensity of SS1P (see Methods). Scale bars, 400 mm.
doi:10.1371/journal.pone.0014640.g004
3D Mesothelioma Spheroids
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cell contacts. Interestingly, the number of tight junctions and
desmosomes seems higher in the core area than the rim area in
spheroids; however, such an increase is modest based on TEM
analysis of three representative spheroids (see Methods) (Fig. 5E)
(p.0.05). Only a few gap junctions are present in spheroids.
The results we obtained from SEM and TEM analysis strongly
suggest that mesothelioma spheroids contain characteristic fea-
tures of MM in vivo and that a greater number of tight junctions
may contribute to the multicellular resistance that we observed
under confocal microscopy in the preceding experiment.
Expression of cell junction proteins
Based on TEM observations, we hypothesized that an altered
expression of intercellular junction molecules might be involved in
the poor penetration of SS1P in mesothelioma spheroids. As
shown in Figure 6, we examined the expression of a panel of cell
contact proteins. Expression of E-Cadherin, a protein involved
with tight junctions, was significantly increased in spheroids. ZO-
1, another tight junction protein, was also modestly increased in
spheroids. However, Connexin-32, the protein responsible for the
formation of gap junctions, was absent in both monolayers and
spheroids. The elevated expression of E-Cadherin in spheroids
found in our study may be related to the increase in the number of
tight junctions, since E-Cadherin plays a crucial role in their
sealing and assembly [20].
Bcl-2 signaling proteins
Previous studies on B cells of chronic lymphocytic leukemia
showed that the mitochondria-dependent Bcl-2 signaling pathway
of apoptosis plays a critical role in the killing of targeted cancer
Figure 5. Electron microscopy of cell contacts in NCI-H226 mesothelioma spheroids. A and B. SEM analysis showing microvilli (arrow).
Scale bars, 200 mm (A) and 10 mm (B). C and D. Ultrathin sections (TEM). Presence of intracellular tight junctions (arrow). Scale bar, 0.5 mm. E. Number
of cellular junctions in the core and rim areas.
doi:10.1371/journal.pone.0014640.g005
3D Mesothelioma Spheroids
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cells by immunotoxins [21]. To examine the potential effects of
Bcl-2 signaling on the resistance of SS1P in tumor spheroids, we
examined the protein expression of several Bcl-2 signaling
molecules in spheroids and monolayers (Fig. 6). Figure 6A shows
an increase of prosurvival Mcl-1 in spheroids as compared to
monolayers. The expression of Bid, Bak and Bax was not changed
in spheroids whereas the expression of Bcl-xL was modestly
increased in spheroids. The expression of Bcl-2 was not detectable
in either spheroids or monolayers. The increased expression of
Mcl-1 may play a role in the inhibition of immunotoxin-induced
apoptosis in spheroids. A previous study indicated that high
expression of Mcl-1 in 3D lung cancer spheroids based on the
H1299 cell line caused its drug resistance [22].
E-Cadherin siRNA silencing and antibody inhibition
To further investigate the role of E-Cadherin in the penetration
of SS1P, we pursued two experimental approaches. First, we
silenced the expression of E-Cadherin using siRNA. As shown in
Fig. 7A, greater than 80% of E-Cadherin protein expression was
reduced in both monolayers and spheroids. As compared to the
off-target siRNA control, E-Cadherin-specific siRNA silencing
sensitized the cells to immunotoxin therapy at 1 ng/mL and
10 ng/mL of SS1P while E-Cadherin knockdown had little
Figure 6. Expression of cell junction and Bcl-2 signaling
proteins in NCI-H226 monolayers and spheroids. A. Protein
expression of E-Cadherin, ZO-1, Connexin-32, Mcl-1, Bcl-xL, Bid, Bak, Bax,
and b-actin examined by Western blot. B. Molecular mechanisms
underlying drug resistance in tumor spheroids.
doi:10.1371/journal.pone.0014640.g006
Figure 7. Sensitizing spheroids to immunotoxin therapy in
vitro. A. Silencing E-Cadherin expression by siRNA. siE-Cad, E-Cadherin
siRNA. 2D: monolayers; 3D: spheroids. B. Silencing E-Cadherin
enhanced the anti-tumor activity of SS1P. Cell growth was assessed
by incubation with WST-8 with values normalized (%) relative to the
growth of the non-silencing siRNA (* p,0.05). C and D. An anti-
adhesive mAb targeting E-Cadherin (SHE78-7) enhanced the anti-tumor
activity of SS1P when added before the formation of spheroids (Pre)
(* p,0.05), but not after (Post). Arrow, lysed cell debris. Scale bars,
400 mm. NS, not significant.
doi:10.1371/journal.pone.0014640.g007
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enhancement at 0.1 ng/mL of SS1P (Fig. 7B). Furthermore, we
added an inhibitory mAb (SHE78-7) against E-Cadherin and
found that it significantly enhanced the anti-tumor activity of SS1P
if the mAb was added before the formation of spheroids (Fig. 7C
and 7D). However, when SHE78-7 was added after the formation
of spheroids, it did not improve SS1P immunotoxin therapy
(Fig. 7D).
Discussion
In the present study, we developed a simple 3D mesothelioma
spheroid model to study how tumor microenvironments affect the
penetration and killing activity of SS1P in vitro. We found that
SS1P was not able to kill greater than 50% of mesothelioma cells
cultured as a spheroid, but killed all of the cells cultured as a
monolayer. To understand this disparity in cytotoxicity, we made
fluorescence-labeled SS1P molecules and established an approach
based on time-course confocal microscopy to examine the
penetration of SS1P within spheroids. We characterized and
quantitatively measured the number of cell junctions in spheroids
by electron microscopy. In addition, we found that the expression
of E-Cadherin, a major protein involved in the sealing and
assembly of tight junctions, was significantly increased in
spheroids.
Two Phase I clinical trials of SS1P were completed at the NCI
in mesothelioma and ovarian cancer patients [12]. Based on Phase
I clinical studies showing the safety of SS1P and its demonstrated
anti-tumor activity, a clinical trial of SS1P in combination with
chemotherapy is currently ongoing in patients with newly
diagnosed pleural mesothelioma. The combination of SS1P with
chemotherapy is based on results from in vivo mouse models
showing marked synergy between SS1P and chemotherapy [23–
26]. Our results indicate that poor penetration is a major
mechanistic factor for the resistance of SS1P in mesothelioma.
Antibody-based drugs enter into solid tumors mainly by a slow
process of diffusion. Due to the fact that immunotoxins have a
relatively short life in circulation (20 minutes in mice and 2–
8 hours in humans) [27], the time that a tumor is exposed to high
immunotoxin concentrations is relatively short. Hence, improving
the penetration of immunotoxins is believed to have an important
impact on their therapeutic effect. In an initial proof-of-concept
study, we pursued two different approaches. In the first approach,
we used siRNA to reduce greater than 80% of the protein
expression of E-Cadherin and found that the anti-tumor activity of
SS1P was significantly enhanced. In the second approach, we used
a mAb (SHE78-7) targeting E-Cadherin to block the adhesive
function of E-Cadherin [28]. Interestingly, we found that the
inhibitory antibody sensitizes the spheroids to immunotoxin
therapy if the antibody was added before the formation of
spheroids but not after. In the present study, we showed how
silencing E-Cadherin expression or blocking its adhesive function
does not completely disrupt spheroids, indicating that E-
Cadherin is not essential for the formation of mesothelioma
spheroids. This observation is consistent with previous studies
indicating participation of integrins, not E-Cadherin, in the early
stages of spheroid formation [29]. In fact, inhibition of integrins
has been shown to enhance breast cancer therapy [30,31].
Nevertheless, previous studies have also shown that E-Cadherin
plays an important role in the morphological transition from
loose cell aggregates to compact spheroids [29]. The fact that
both siRNA silencing and antibody inhibition targeting E-
Cadherin enhanced immunotoxin therapy in the NCI-H226
spheroid model warrants further investigation of E-Cadherin as a
target for mesothelioma therapy.
It has been suggested that the Bcl-2 signaling pathway of
apoptosis plays an important role in the killing of targeted cancer
cells by immunotoxins [21]. A recent study illustrated that the
overexpression of Mcl-1 and Bcl-xL inhibited PE immunotoxin-
induced cancer cell death [32]. A previous study also revealed that
high expression of Mcl-1 in 3D lung cancer spheroids caused its
drug resistance [22]. In the present study, we demonstrated an
increase of Mcl-1 in spheroids as compared to monolayers,
indicating that the 3D mesothelioma spheroid model had acquired
Bcl-2 signaling apoptotic resistance as well as multicellular
resistance.
This work is one of the first to investigate immunotoxins in 3D
tumor spheroids in vitro. The method described may allow for
further investigations of the tumor microenvironmental effects on
drug penetration and tumor cell killing and has applications for the
studies of other tumor-targeting antibodies and immunoconjugates
in vitro. We also understand that some features of solid cancers that
are not modeled by spheroids include the influence of stroma and
immune cells. Nevertheless, spheroids offer an advantage based on
the ability to examine the distribution of drugs in the absence of
complicating factors such as pharmacokinetics, which often differ
between mice and humans [33].
We believe this method has additional applications for
identifying novel molecular targets in tumors. We show in this
work that E-Cadherin is highly expressed in 3D mesothelioma but
not in monolayers. Interestingly, E-Cadherin is among one of the
most important biomarkers that have been proposed as useful in
the diagnosis of MM [34,35]. It will be of great interest to further
evaluate E-Cadherin and other cell adhesion molecules as
potential therapeutic targets in mesothelioma.
Supporting Information
Video S1 Time-lapse penetration of immunotoxin in spheroids
by confocal microscopy (green fluorescence).
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Video S2 Time-lapse penetration of immunotoxin in spheroids
by confocal microscopy (overlay of bright field and fluorescence
images).
Found at: doi:10.1371/journal.pone.0014640.s002 (9.74 MB AVI)
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